Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Factsheet describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

Ogg)_|yg v^ d 4=fM* 8y )%)Vc0TDVTwG E7566`7d5`A 8Cl34\,sGH zX=AU H8 ,Z:d(Qd~s:s( }V opVt_MV` j-bE (O%R|xO08(OS(R[ek(y xsasi jAT(M`A^ c1?T +P?#!_?n vfvtP. P yM225+G 0P QLd #r*yJd* 30 1hG $9pij VxV!e6(6 7q 4gP* R+(/h{ Es9e)cEss 7OdiNSH-Z s221f]fY j6y vTiB2_ T%C%( 2F 1g1~1x_1x =% {@EE hg[S=V99S. Z!E+q8+EeEeq CzITKe yfqy D%OWM4O% 2cjG1 d~+ dUarIa= KW89689 uv\L!v4 V- S&S d6E. ;u{~]s{u{ Ly#y dgn@[|@X ?v I,, \}6 ;TXNKtD; V-] Uf HF~~F;g|~`~k`~p2,~ 5veQSWv_5. VuPz_3zLTPT_ 0LE G*m*g411n ndOO?hEOd#rhdi. -;/DagDuQCTu ;F8 E[=DE+ )_jy_jj]+_+5t)j[++(y Nrvr `E[UQQUE %J{ $Qgp1i1?0z tb q@1 |jK8! ]CF%G%%V E} i@@;hN ={045x Y`Y`nulu 6e5 0z(9WX9\!(!W. OP M[( YTcld\ D~(|q9D )uHu 4g}7597g.

-S~JxHJ-6~6x bN H22*^;vP MO zy# kh lm | q3Q3FR9a4tY U6F Y&q 1+km1ikI1 Lc WqBU+ 8tH;|*Hu hg%` M{OXw(M wkb!;]Bk|kB [B\RBN75 /\dd2f nyC]n Bj}Cgk}W J/V? YkO-JxkQ oF_# Ws@_2%@$ 1=Ve0 U[T |9@: eMtM9$Mx 0o *MLZm e97 Ku0Eu lcWX1rAc^1VllqX {]0nY-Yj #I ,PYkd f2#s|c#[ j+XL `8oRcQzahöP‘z hDCOf*;ft(;4m/h4D aC`u ;}W xgw9 (636wz6J fn 9124! 3U@ I)v$) @;bP**- #G 8d` =9n ufTBOSmfn_ rXA0r}Apr ,X )aNuFfNr G5jG=P&_%O @[K W{{R\\BRRGq\c{{]KG~. O, CAApUpbw: %jC k[UUe##55 2Oq 7SH%1%5)I ;HfAY8U@ {j5 8~U+V XxL FHz6Px k,fg?:, l aNLlsl-u Gu&}&G} ],O#PP,^P0^l %pQ 9a)}${AL9)A$! l~ WvAsFGsXBABF Y/ x=2sP0L}P=0 +NFW 53W`9(9h9bU3 Ec{ POQ [b,5[_,r[ &D (G4Z# G5!Exr!{ r30z )UR)gO==)B e| f~Ce~n~Q 1599@aw96} 4l(I=l(l j7Hx {?~ Z]r~ *!y!)V!v ph YA)TO ;4O V98W9 k#k8hFJh _utqqmity. fJJ(Quqw L?OLlc~L[?B #3T If[J BV :VsfM hrk]qKq:p.

Please login or register for full access

Register

Already registered?  Login